Endowments Quietly Accumulate Positions in Royalty Pharma Secondary Stakes

The Secondary Market No One Is Talking About

Royalty Pharma occupies an unusual corner of finance: it buys royalty interests on approved drugs and late-stage drug candidates, collecting a percentage of net sales without running clinical trials or manufacturing anything. The business model is elegant in its passivity – capital goes in, royalty checks come out, sometimes for decades. What makes the current moment notable is not the company itself, but who has been quietly acquiring secondary stakes in its existing royalty streams through the private market.

University endowments – particularly those managing between $3 billion and $15 billion in assets – have been building positions in secondary stakes tied to Royalty Pharma’s portfolio. These are not open-market purchases of RPRX shares. They are private transactions where one institutional holder sells a fractional economic interest in a specific royalty stream, and an endowment steps in as the buyer, bypassing the public equity wrapper entirely.

The distinction matters enormously for how these positions appear on balance sheets.

Why Endowments Prefer the Secondary Route

The appeal for endowments is structural. When an institution buys publicly traded Royalty Pharma shares, it gets exposure to the entire portfolio, the management overhead, the corporate cost structure, and the volatility of public markets. When it acquires a secondary stake in a specific royalty – say, a royalty interest tied to a blockbuster oncology drug with 12 years of remaining patent life – it gets a cleaner, more predictable cash flow profile that can be modeled with relative precision. Endowments running liability-matched strategies or targeting specific return corridors find this kind of isolation genuinely useful.

Secondary transactions also arrive at a discount to face value. The original holder may need liquidity for portfolio rebalancing, or may simply have reached the end of a fund’s life cycle, creating price pressure that has nothing to do with the underlying royalty’s performance. Endowments, which operate with indefinite time horizons and low liquidity needs, are structurally positioned to absorb that discount and wait out the remaining cash flow runway. This is the same logic that draws endowments into infrastructure royalty streams, where long-duration assets generate friction in seller markets but reward patient capital.

There is also a diversification argument that is easy to underestimate. Pharmaceutical royalties are weakly correlated with equity markets, credit spreads, and real estate cycles. A royalty tied to an immunology drug does not care whether the S&P 500 falls 20% or whether commercial real estate refinancing costs spike. For endowments managing portfolios where true diversification is increasingly difficult to find, that low correlation is not a minor bonus – it is the central investment thesis.

The Mechanics of a Secondary Stake Transaction

These transactions typically originate when a dedicated royalty fund or a life sciences-focused private equity vehicle needs to wind down. The fund manager identifies buyers willing to step into the economic position without triggering a full portfolio sale. Endowments may work through a placement agent or approach sellers directly through their alternative assets teams. Pricing is generally negotiated around a net present value calculation applied to projected royalty cash flows, with the discount rate reflecting both credit risk and the uncertainty embedded in future drug sales volumes.

Legal structuring can be complex. Royalty interests are not standardized instruments, and the underlying agreements between Royalty Pharma and the original drug developer often contain transfer restrictions, consent rights, or change-of-control provisions that must be navigated. Endowment legal and compliance teams spend considerable time on diligence around the transferability of the interest itself before any pricing conversation becomes serious. Some transactions take 12 to 18 months to close from initial term sheet to capital transfer.

Once closed, the position sits in the endowment’s alternatives bucket, typically alongside private credit or real assets. Mark-to-market treatment varies by institution – some use a trailing royalty yield methodology updated quarterly, others hold at cost and adjust only at defined intervals. This accounting flexibility, combined with the position’s illiquidity, means the volatility that endowment trustees see on their reporting statements looks nothing like what a public equity investor in RPRX experiences on a daily basis.

What This Signals About Endowment Strategy

The accumulation of these positions reflects a broader hunt for yield that does not come bundled with duration risk from fixed income or correlation risk from equities. Pharmaceutical royalties offer something rare: cash flows with a biological clock tied to patent expiration rather than an interest rate cycle. That feature becomes especially attractive when rate environments are uncertain and the conventional toolkit for managing portfolio income starts to look unreliable.

There is a selection effect at work in which royalties attract the most interest. Endowments are not buying stakes in early-stage royalty streams where drug approval risk still looms. The target positions cluster around approved drugs with established sales trajectories – ideally in therapeutic areas like oncology, rare disease, or immunology, where pricing power has historically held even under payer pressure. A royalty on a drug generating $2 billion in annual sales is a materially different risk profile than one tied to a drug still in Phase III.

The quiet nature of this accumulation is partly strategic and partly structural. Secondary transactions in private royalty interests do not require public disclosure unless the position crosses certain reporting thresholds. Endowments operating in this space are under no obligation to advertise their activity, and they have little incentive to do so – drawing attention to an attractive secondary market only increases competition and compresses the discounts that make the trade worthwhile in the first place. The endowments best positioned to continue building these stakes are the ones that identified the opportunity before it became consensus.